BI Analyst Briefing: CAR-T Expert Call
Kite’s axi-cel is likely to be the first CAR-T to be approved for treating lymphoma, which is the most attractive blood cancer opportunity for this novel therapy. But there are many nuances of the market in terms of when and where CAR-T would be used. Gilead’s $12 billion bid for Kite also implies it envisions broader use earlier in the treatment paradigm. But in buying the commercial spoils, Gilead also inherits the challenges of launching a CAR-T therapy. It could also have competition from Novartis in its near-term horizon. Meanwhile, Juno is boldly suggesting the treatment could make its way into the outpatient setting.
Bloomberg Intelligence will be teaming up with inThought Research to host Dr. Josh Brody, head of the Lymphoma Immunotherapy program @ Mt Sinai, to better understand the opportunity behind one of the most anticipated launches of this decade.
- Marc Engelsgjerd, MD, inThought oncology lead
- Asthika Goonewardene, Senior Biotech Analyst, Bloomberg Intelligence
- Josh Brody MD, director of the Lymphoma Immunotherapy Center at Mt. Sinai
- Christine Keaveney RN, main financial coordinator for the Mt Sinai transplant group